Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients

Table 2 Risk factors for development of DLR among non-Hodgkin’s lymphoma patients with HBV reactivation during chemotherapy

	DLR (-)			DLR (+)
	Total	n	%	n	%	P
Number of patients	31	16	51.6	15	48.4
Age (yr)
≤45	11	4	36.4	7	65.6	0.2734
>45	20	12	60	8	40
Sex
Female	14	7	50	7	50	1
Male	17	9	52.9	8	47.1
GPT>10X
Yes	19	8	42.1	11	57.9	0.2734
No	12	8	66.7	4	33.4
HBeAg
Present	29	16	55.2	13	44.8	0.2258
Absent	2	0	0	2	100
HBV genotype C
No	21	13	61.9	8	38.1	0.0768
Yes	7	1	14.3	6	85.7
Unknown or mixed type	3	2	66.7	1	33.3
Total bilirubin >5
Yes	5	1	20	4	80	0.1719
No	26	15	57.7	11	42.3
Peak HBV DNA >100X
Yes	18	9	50	9	50	1
No	13	7	53.8	6	46.2
Patterns of reactivation
Transient	16	10	62.5	6	37.5	0.508
Protracted/resolved	5	3	60	2	40
Protracted/unresolved	5	1	20	4	80
Multiple reactivation	3	1	33.3	2	66.7
Unknown	2	1	50	1	50